Background Ultra-short coeliac disease (USCD) is defined as villous atrophy only present in the duodenal bulb (D1) with concurrent positive coeliac serology. We present the first, multicentre, international study of patients with USCD. Methods Patients with USCD were identified from 10 tertiary hospitals (6 from Europe, 2 from Asia, 1 from North America and 1 from Australasia) and compared with age-matched and sex-matched patients with conventional coeliac disease. Findings Patients with USCD (n=137, median age 27 years, IQR 21–43 years; 73% female) were younger than those with conventional coeliac disease (27 vs 38 years, respectively, p<0.001). Immunoglobulin A-tissue transglutaminase (IgA-tTG) titres at index gastroscopy were lower in patients with USCD versus conventional coeliac disease (1.8×upper limit of normal (ULN) (IQR 1.1–5.9) vs 12.6×ULN (IQR 3.3–18.3), p<0.001). Patients with USCD had the same number of symptoms overall (median 3 (IQR 2–4) vs 3 (IQR 1–4), p=0.875). Patients with USCD experienced less iron deficiency (41.8% vs 22.4%, p=0.006). Both USCD and conventional coeliac disease had the same intraepithelial lymphocytes immunophenotype staining pattern; positive for CD3 and CD8, but not CD4. At follow-up having commenced a gluten-free diet (GFD) (median of 1181 days IQR: 440–2160 days) both USCD and the age-matched and sex-matched controls experienced a similar reduction in IgA-tTG titres (0.5 ULN (IQR 0.2–1.4) vs 0.7 ULN (IQR 0.2–2.6), p=0.312). 95.7% of patients with USCD reported a clinical improvement in their symptoms. Interpretation Patients with USCD are younger, have a similar symptomatic burden and benefit from a GFD. This study endorses the recommendation of D1 sampling as part of the endoscopic coeliac disease diagnostic workup.
We read, with interest, the paper entitled “In Elderly Anemic Patients without Endoscopic Signs of Bleeding Are Duodenal Biopsies Always Necessary to Rule Out Celiac Disease
Introduction A gluten-free diet (GFD) is the primary treatment for patients with coeliac disease. The current options for checking adherence are through dietary questionnaires and serological markers (IgA-tTG and IgA-EMA), however a recent meta-analysis showed a poor relationship between serological markers & the presence of villous atrophy. Novel gluten immunogenic peptides (GIP), resistant to gastrointestinal digestion, can be measured in urine and stool. We are presenting the largest data set looking at the relationship between dietary questionnaires (assessing for exposure to gluten), serology and urinary markers for GIP in adult patients with coeliac disease. Methods We assessed adult patients being investigated for coeliac disease (n= 105) with a gastroscopy and duodenal biopsy and adult patients with known coeliac disease (n=172) having a biopsy to assess for remission. Patients had concurrent biopsies, serological testing and urinary GIP. For patients with established coeliac disease, dietary adherence questionnaires were also used (Biagi & CDAT). Results In total, 277 patients were recruited (71% female, median 57years). A positive GIP significantly correlated to a positive IgA-EMA, IgA-tTG and the presence of villous atrophy (p<0.005, p=0.03 and p<0.005 respectively). Results of both adherence questionnaires were similar to each other (p=0.03) but neither CDAT or Biagi correlated to a positive IgA-EMA (p=0.35 and p=0.25 respectively), or a positive IgA-tTG (p=0.37 and p=0.51 respectively), or a positive GIP (p=0.53 and p=0.50 respectively), or the presence of villous atrophy (p=0.61 and p=0.15 respectively). Combining GIP and serological markers for recognising villous atrophy had a sensitivity, specificity, PPV and NPV of 53%, 88%, 90% and 47% respectively. Conclusion There is poor agreement between self-reported adherence to a GFD and serological or urinary markers; this suggests that patients may not be aware of their exposure to gluten or are deliberately not disclosing gluten ingestion. Serological and urinary markers are more accurate than questionnaires for recognising non-adherence to a GFD.
Introduction Ultra-short coeliac disease (USCD) patients have villous atrophy limited to the duodenal bulb. There is a paucity of data on the clinical presentation and prognosis of patients with USCD. This study therefore aimed to assess this in the largest cohort of patients with USCD. Methods All USCD patients diagnosed in or referred to Sheffield were identified (Group 1) and their case notes reviewed. USCD patients were then compared to age and sex matched patients with conventional coeliac disease (CD) (Group 2). Age and sex of USCD patients were compared to all 2636 adult CD patients treated in Sheffield over 20 years (Group 3). Patients with USCD were then followed up to assess adherence to the gluten-free diet using the validated Biagi questionnaire. Results Both Group 1 and 2 had 64 patients each (median age 28 years, IQR 25, 71.9% female). Patients with USCD, Group 1, were younger than Group 3 (median 28.00 vs 44.00 respectively, p<0.001). There was no difference in sex (p=0.433). Tissue transglutaminase (tTG), measured at index gastroscopy, was lower in patients with USCD than CD (median 1.86 vs. 10.43 times the upper limit of normal (ULN), p<0.001). Both patients with USCD and CD had improved tTG titres at 1 year (0.57ULN, p<0.001 and 1.13ULN, p<0.001 respectively). There was no significant difference in EMA results at the time of index gastroscopy. There was no difference in the number of gastrointestinal symptoms reported by patients in Group 1 or 2 (p=0.465) nor haematinic, ferritin or vitamin D deficiencies (p=0.195). There was also no significant difference in human leukocyte antigen genotyping or dual-energy x-ray absorptiometry results between the groups. Duodenal bulb biopsies improved at 1 year, though this was not statistically significant for patients with USCD or CD (p=0.285 and p=0.066 respectively). At follow up, patients with USCD were just as keen to follow a gluten-free diet as those with CD (61.0% and 39.1% scored 3 out a maximum of 4 respectively, p=0.143). Both groups also demonstrated a significant improvement in fatigue at follow up (p=0.039 and p=0.013 respectively). Conclusions USCD patients are a younger cohort than conventional CD, but they have a similar symptomatic burden and haematinic disturbances. USCD patients are keen to adhere to the gluten-free diet, so their diagnosis should not be dismissed.